SCHEMBL6077635

SCHEMBL6077635

CC1(C)OC(=O)/C(=C\C(=O)NCc2ccc(Cl)c(Cl)c2)O1

nearest known ligand 0.50

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
TSHR P16473 2/20 0.49
MEN1 O00255 2/20 0.46
KMT2A Q03164 2/20 0.46
ALDH1A1 P00352 1/20 0.46
HPGD P15428 1/20 0.46
SMN1; SMN2 Q16637 1/20 0.45
TRPV1 Q8NER1 3/20 0.42
P2RX7 Q99572 1/20 0.41
APEX1 P27695 1/20 0.41
LMNA P02545 3/20 0.40
ESR1 P03372 1/20 0.40
NR3C1 P04150 1/20 0.40
PGR P06401 1/20 0.40
NR3C2 P08235 1/20 0.40
ESR2 Q92731 1/20 0.40
TP53 P04637 1/20 0.40
HRH3 Q9Y5N1 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6077638 1.00 TSHR (0.49) TSHRMEN1KMT2AALDH1A1HPGD
SCHEMBL14833087 0.86 LIPG (0.45)
SCHEMBL6077948 0.86 LIPG (0.45)
SCHEMBL6078282 0.83 TRPV1 (0.39) ALDH1A1TRPV1P2RX7
SCHEMBL6078276 0.83 TRPV1 (0.39) ALDH1A1TRPV1P2RX7
SCHEMBL14833095 0.82 LIPG (0.46) MEN1KMT2AALDH1A1HPGDSMN1; SMN2
SCHEMBL14833096 0.82 LIPG (0.46) MEN1KMT2AALDH1A1HPGDSMN1; SMN2
SCHEMBL6078895 0.81 ALDH1A1 (0.46) TSHRMEN1KMT2AALDH1A1HPGD
SCHEMBL6078900 0.81 ALDH1A1 (0.46) TSHRMEN1KMT2AALDH1A1HPGD
SCHEMBL6419473 0.81 TP53 (0.38) TSHRALDH1A1SMN1; SMN2LMNATP53

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7109186-B2 4-hydroxy-5-oxo-1-(2-[4-methylpiperazin-1-yl]ethyl)-2,5-dihydro-1H-pyrrole-3-carboxylic acid (3,4-dichlorobenzyl)-methyl-amide for human immunodeficiency virus (HIV) treatment BRISTOL-MYERS SQUIBB COMPANY (US) 2006-09-19 US disclosed
US-20040110804-A1 HIV integrase inhibitors BRISTOL-MYERS SQUIBB COMPANY 2004-06-10 US disclosed
WO-2004004657-A2 HIV INTEGRASE INHIBITORS BRISTOL-MYERS SQUIBB COMPANY (US) 2004-01-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040110804-A1 HIV integrase inhibitors CDKN1A, SAMHD1, CTCF TSHR 4830/4885MEN1 4784/4885KMT2A 736/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.